Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, Radford J, Heo DS, Park HY, Pro B, Jayamohan J, Visco C, Scarfò L, Zucca E, Gospodarowicz M, Christie D; International Extranodal Lymphoma Study Group (I.E.L.S.G.). Messina C, et al. Among authors: porter d. Br J Haematol. 2014 Mar;164(6):834-40. doi: 10.1111/bjh.12714. Epub 2014 Jan 2. Br J Haematol. 2014. PMID: 24383942 Free article.
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).
Govi S, Christie D, Mappa S, Marturano E, Bruno-Ventre M, Messina C, Medina EA, Porter D, Radford J, Heo DS, Park Y, Pro B, Jayamohan J, Pavlakis N, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group. Govi S, et al. Among authors: porter d. Leuk Lymphoma. 2014 Aug;55(8):1796-9. doi: 10.3109/10428194.2013.853298. Epub 2014 Feb 4. Leuk Lymphoma. 2014. PMID: 24295130
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study).
Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, Radford J, Heo DS, Park Y, Martinelli G, Taylor E, Lucraft H, Hong A, Scarfò L, Zucca E, Christie D; International Extranodal Lymphoma Study Group. Bruno Ventre M, et al. Among authors: porter d. Oncologist. 2014 Mar;19(3):291-8. doi: 10.1634/theoncologist.2013-0249. Epub 2014 Feb 24. Oncologist. 2014. PMID: 24567283 Free PMC article.
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial.
Christie D, Dear K, Le T, Barton M, Wirth A, Porter D, Roos D, Pratt G. Christie D, et al. Among authors: porter d. Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1164-70. doi: 10.1016/j.ijrobp.2010.03.036. Epub 2010 Jul 16. Int J Radiat Oncol Biol Phys. 2011. PMID: 20638196 Clinical Trial.
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: porter dl. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication.
Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, Kim S, Naing SY, Richardson MW, Vogel AN, Maldini CR, Kong H, Liu X, Lacey SF, Bauer AM, Mampe F, Richman LP, Lee G, Ando D, Levine BL, Porter DL, Zhao Y, Siegel DL, Bar KJ, June CH, Riley JL. Tebas P, et al. Among authors: porter dl. J Clin Invest. 2024 May 1;134(9):e181576. doi: 10.1172/JCI181576. J Clin Invest. 2024. PMID: 38690741 Free PMC article. No abstract available.
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.
Hedskog C, Spinner CD, Protzer U, Hoffmann D, Ko C, Gottlieb RL, Askar M, Roestenberg M, de Vries JJC, Carbo EC, Martin R, Li J, Han D, Rodriguez L, Parvangada A, Perry JK, Ferrer R, Antón A, Andrés C, Casares V, Günthard HF, Huber M, McComsey GA, Sadri N, Aberg JA, van Bakel H, Porter DP. Hedskog C, et al. Among authors: porter dp. Viruses. 2024 Mar 31;16(4):546. doi: 10.3390/v16040546. Viruses. 2024. PMID: 38675889 Free PMC article. Clinical Trial.
1,840 results